ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Early Rheumatoid Arthritis"

  • Abstract Number: 1424 • 2017 ACR/ARHP Annual Meeting

    Impact of Glucocorticoid Therapy on the Efficacy of SC Abatacept or Adalimumab in RA Patients with Inadequate Response to MTX: A Post Hoc Analysis of Data from a Head-to-Head Trial

    Yannick Degboé1,2, Michael Schiff3, Michael Weinblatt4, Roy Fleischmann5, HA Ahmad6 and Arnaud Constantin2,7, 1Toulouse University Hospital, Toulouse, France, 2Université Paul Sabatier, Toulouse, France, 3University of Colorado, Denver, CO, 4Brigham and Women’s Hospital, Boston, MA, 5University of Texas Southwestern Medical Center, Dallas, TX, 6Bristol-Myers Squibb, Princeton, NJ, 7Purpan University Hospital, Toulouse, France

    Background/Purpose: In patients with RA, low-dose glucocorticoids (GCs) have been shown to increase clinical, functional and radiographic efficacy when combined with conventional synthetic DMARDs;1 however,…
  • Abstract Number: 1445 • 2017 ACR/ARHP Annual Meeting

    Effect of Methotrexate (MTX), and MTX Plus Colchicine (CCH) on the Expression and Activity of NLRP3 Inflammasome in Patients with Early Rheumatoid Arthritis (RA)

    Dolores Ramos-Bello1, Crisol Alvarez-Quiroga2, Georgina Aguilera Barragán-Pickens3, Angel Javier Pedro Martínez3, Tania Adriana Luna-Zúñiga3, Georgina Martínez-Flores3, Eduardo Saul Acevedo-Castañeda4, Homero López-Ferretis3, Enrique Cuevas-Orta3, Eva Santillan-Guerrero3, Ricardo Moreno-Valdez3, Martín Saldaña-Baarnard3, Marco Ulises Martinez-Martinez5, David Herrera Van Oostdam6, Roberto González-Amaro7 and Carlos Abud-Mendoza8, 1Reumatología, Unidad Regional de Reumatologia y Osteoporosis Hospital Central "Dr. Ignacio Morones Prieto" y Facultad de Medicina de la UASLP, San Luis Potosi, Mexico, 2División de Medicina Molecular y Traslacional, Centro de Investigación en Ciencias de la Salud y Biomedicina, UASLP, San Luis Potosí, Mexico, 3Unidad Regional de Reumatologia y Osteoporosis Hospital Central "Dr. Ignacio Morones Prieto" y Facultad de Medicina de la UASLP, San Luis Potosí, Mexico, 4Medicina Interna, Unidad Regional de Reumatologia y Osteoporosis Hospital Central "Dr. Ignacio Morones Prieto" y Facultad de Medicina de la UASLP, San Luis Potosí, Mexico, 5Unidad de Investigaciones Reumatológicas, Faculty of Medicine, Universidad Autónoma de San Luis Potosí and Hospital Central, San Luis Potosí, Mexico, 6Unidad de Investigaciones Reumatológicas, Hospital Central & Facultad de Medicina, Universidad Autónoma de San Luis Potosí, San Luis Potosí, Mexico, 7Inmunología, Facultad de Medicina de la UASLP, San Luis Potosí, Mexico, 8Unidad de Investigaciones Reumatológicas y Osteoporosis, Faculty of Medicine, Universidad Autónoma de San Luis Potosí and Hospital Central, San Luis Potosí, Mexico

    Background/Purpose: NLRP3 inflammasome is an intracellular protein complex involved in the production of pro-inflammatory cytokines as IL-1β and IL-18, which has been reported to have…
  • Abstract Number: 122 • 2017 ACR/ARHP Annual Meeting

    Poor Prognostic Factors at the Start of Methotrexate Therapy Are Not Associated with Worse Treatment Response: Results from the Rheumatoid Arthritis Medication Study

    JM Gwinnutt1, Kimme L. Hyrich1, M Lunt1, Darren Plant1, M Brazil2, R Postema2, Anne Barton1 and Suzanne M Verstappen1, 1Manchester Academic Health Science Centre, Manchester, United Kingdom, 2Bristol-Myers Squibb, Uxbridge, United Kingdom

    Background/Purpose: As anti-citrullinated protein antibody positivity (+), RF+ and erosions are independently associated with poor outcomes in patients (pts) with RA, clinicians may use these…
  • Abstract Number: 1465 • 2017 ACR/ARHP Annual Meeting

    Cost per Response for Abatacept Versus Adalimumab in Patients with Seropositive, Erosive, Early Rheumatoid Arthritis in the US, Germany, Spain and Canada

    J Foo1, JM Rodriguez Heredia2, C Polanco Sánchez3, M Mtibaa4, KH Herrmann5, E Alemao6, R Postema7 and C Baerwald8, 1Mapi Group, Houten, Netherlands, 2Hospital Universitario de Getafe, Madrid, Spain, 3Bristol-Myers Squibb, Madrid, Spain, 4Bristol-Myers Squibb, Montréal, QC, Canada, 5Bristol-Myers Squibb, Munich, Germany, 6Bristol-Myers Squibb, Princeton, NJ, 7Bristol-Myers Squibb, Uxbridge, United Kingdom, 8University Hospital, Department of Internal Medicine, Rheumatology Unit, Leipzig, Germany

    Background/Purpose: RA is a chronic, inflammatory disorder leading to disability and reduced quality of life. Effective treatment with biologic DMARDs poses a significant economic burden.…
  • Abstract Number: 235 • 2017 ACR/ARHP Annual Meeting

    MRI in Rheumatoid Arthritis: Does Quantifying the Number of Erosive Lesions Improve Detection of Subtle Erosive Progression Compared to the Omeract RA MRI Scoring System?

    Ulf Sundin1, Anna-Birgitte Aga2, Tore K Kvien3, Siri Lillegraven4 and Espen A. Haavardsholm4, 1*Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 2Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 3Diakonhjemmet Hospital, Oslo, Norway, 4Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway

    Background/Purpose: Early detection of erosive progression is an important application of MRI in RA. For research purposes the OMERACT Rheumatoid Arthritis MRI Scoring system (RAMRIS)…
  • Abstract Number: 1820 • 2017 ACR/ARHP Annual Meeting

    Sustained Effectiveness after Remission Induction with Methotrexate and Step-Down Glucocorticoids in Patients with Early Rheumatoid Arthritis Following a Treat-to-Target Strategy after 2 Years

    Veerle Stouten1, Johan Joly2, Diederik De Cock1, Sofia Pazmino1, Kristien Van der Elst2,3, René Westhovens1,2 and Patrick Verschueren1,2, 1KU Leuven Department of Development and Regeneration, Skeletal Biology and Engineering Research Center, Leuven, Belgium, 2University Hospitals Leuven on behalf of the CareRA Study Group, Leuven, Belgium, 3KU Leuven, Department of Public Health and Primary Care, Skeletal Biology and Engineering Research Center, Leuven, Belgium

    Background/Purpose: Remission induction with methotrexate (MTX) and a moderate-dose, step-down scheme of Glucocorticoids (GC), (COBRA Slim strategy), showed equally high remission rates at year 1…
  • Abstract Number: 595 • 2016 ACR/ARHP Annual Meeting

    Cinical Responses and Improvements in Patient-Reported Outcomes Are Associated with Increased Productivity in the Workplace and at Home in Rheumatoid Arthritis Patients Treated with Certolizumab Pegol

    Vivian P. Bykerk1, Paul Emery2, Michael Weinblatt3, Gerd-Rüdiger Burmester4, Daniel E. Furst5, Xavier Mariette6, Ronald van Vollenhoven7, Oana Purcaru8, Pauline Ralston9 and Clifton Bingham III10, 1Divison of Rheumatology, Hospital for Special Surgery, New York, NY, 2University of Leeds, Midlothian, United Kingdom, 3Brigham and Women’s Hospital, Boston, MA, 4Charité – University Medicine Berlin, Berlin, Germany, 5David Geffen School of Medicine at UCLA, Los Angeles, CA, 6Université Paris-Sud, Paris, France, 7Amsterdam Rheumatology and Immunology Center (ARC), Amsterdam, Netherlands, 8UCB Pharma, Slough, United Kingdom, 9Hays Pharma, London, United Kingdom, 10Johns Hopkins University, Baltimore, MD

    Background/Purpose: Rheumatoid arthritis (RA) is associated with work disability, loss of productivity and reduced quality of life. In established and early RA, compared with MTX…
  • Abstract Number: 2480 • 2016 ACR/ARHP Annual Meeting

    Dose-Related Short Term Clinical Response to Initial Treatment with Methotrexate in Mono- and Combination Therapy in Early Rheumatoid Arthritis Patients – a Meta-Regression Analysis

    SA Bergstra1, CF Allaart1, T Stijnen2 and RBM Landewé3,4, 1Department of Rheumatology, LUMC, Leiden, Netherlands, Leiden, Netherlands, 2Department of Medical Statistics, LUMC, Leiden, Netherlands, Leiden, Netherlands, 3Zuyderland Medical Center, Heerlen, Netherlands, Heerlen, Netherlands, 4Amsterdam Rheumatology & Immunology Center, Netherlands, Amsterdam, Netherlands

    Background/Purpose: Recently, there has been a trend to start methotrexate (MTX) in higher doses, either as monotherapy or in combination with other drugs in rheumatoid…
  • Abstract Number: 608 • 2016 ACR/ARHP Annual Meeting

    Initial Intensive Therapy of Adalimumab and Methotrexate Is Associated with Long-Term Structural Remission and Low Disease Activity after Adalimumab Discontinuation Is Maintained up to 3 Years in Japanese Patients: Hopeful-3 Study

    Yoshiya Tanaka1, Hisashi Yamanaka2, Naoki Ishiguro3, Nobuyuki Miyasaka4, Katsuyoshi Kawana5, Naoki Agata5 and Tsutomu Takeuchi6, 1University of Occupational and Environmental Health, Kitakyushu, Japan, 2Tokyo Women's Medical University, Tokyo, Japan, 3Department of Orthopedic Surgery, Nagoya University, Graduate School & Faculty of Medicine, Nagoya, Japan, 4Tokyo Medical and Dental University, Tokyo, Japan, 5Abbvie GK, Tokyo, Japan, 6Division of Rheumatology, Keio University School of Medicine, Tokyo, Japan

    Background/Purpose:   Methods:   Of 172 patients enrolled, 135 (ADA continuation, n=61; ADA discontinuation, n=74) with DAS28–CRP at both week 52 (start of HOPEFUL-2) and week 208…
  • Abstract Number: 2498 • 2016 ACR/ARHP Annual Meeting

    Tender Joints Is a Consistent Negative Predictor of Sustained Remission in Aggressively Treated Patients with Early Rheumatoid Arthritis

    Nina P. Sundlisater1, Siri Lillegraven1, Inge C Olsen1, Anna-Birgitte Aga1, Hilde B. Hammer2, Till Uhlig1, Desiree van der Heijde1,3, Tore K Kvien1 and Espen A. Haavardsholm1, 1Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 2Dept. of Rheumtology, Diakonhjemmet Hospital, Oslo, Norway, 3Dept of Rheumatology, Leiden University Medical Ctr, Leiden, Netherlands

    Background/Purpose: Rheumatoid arthritis (RA) care has moved towards early diagnosis and treatment to improve long-term patient outcomes. Our objective was to assess prognostic factors for…
  • Abstract Number: 952 • 2016 ACR/ARHP Annual Meeting

    A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study Evaluating Treatment Strategies (Continuation Versus Withdrawal) for Maintaining Low Disease Activity after 1 Year of Certolizumab Pegol in DMARD-Naive Patients with Early and Progressive, Active RA

    Michael Weinblatt1, Clifton Bingham III2, Gerd-Rüdiger Burmester3, Vivian P. Bykerk4, Daniel E. Furst5, Xavier Mariette6, Désirée van der Heijde7, Ronald van Vollenhoven8, Brenda VanLunen9, Cécile Ecoffet10, Christopher Cioffi9 and Paul Emery11, 1Brigham and Women's Hospital, Boston, MA, 2Johns Hopkins University, Baltimore, MD, 3Charité – University Medicine Berlin, Berlin, Germany, 4Divison of Rheumatology, Hospital for Special Surgery, New York, NY, 5David Geffen School of Medicine at UCLA, Los Angeles, CA, 6Université Paris-Sud, Paris, France, 7Leiden University Medical Center, Leiden, Netherlands, 8Amsterdam Rheumatology and Immunology Center (ARC), Amsterdam, Netherlands, 9UCB Pharma, Raleigh, NC, 10UCB Pharma, Brussels, Belgium, 11University of Leeds, Leeds, United Kingdom

    Background/Purpose: There is interest in tapering or stopping biologic DMARD therapy in RA patients (pts) who have achieved sustained disease control.1 We report the results…
  • Abstract Number: 2525 • 2016 ACR/ARHP Annual Meeting

    Patient Characteristics Predicting Remission Using Intensive Treatment Strategies in  Early Rheumatoid Arthritis

    Diederik Decock1, Rene Westhovens1,2, Veerle Stouten1, Kristien Van der Elst2,3, Johan Joly2, Patrick Verschueren1,2 and CareRA study group, 1KU Leuven Department of Development and Regeneration, Skeletal Biology and Engineering Research Center, Leuven, Belgium, 2Rheumatology, University Hospitals Leuven, Leuven, Belgium, 3KU Leuven, Department of Public Health and Primary Care, Skeletal Biology and Engineering Research Center, Leuven, Belgium

    Background/Purpose: Guidelines recommend to treat newly diagnosed Early Rheumatoid Arthritis (ERA) with intensive treatment strategies using Methotrexate (MTX) or a combination of csDMARDs and a…
  • Abstract Number: 956 • 2016 ACR/ARHP Annual Meeting

    The Effect of Treatment Adjustments Aimed at DAS Remission on Physical Functioning in Undifferentiated and Rheumatoid Arthritis Patients in Low Disease Activity

    SA Bergstra1, OM Olivas Vergara1, G Akdemir1, GM Steup-Beekman2, HK Ronday3, JB Harbers4, RBM Landewé5,6 and CF Allaart1, 1Department of Rheumatology, LUMC, Leiden, Netherlands, Leiden, Netherlands, 2Department of Rheumatology, Bronovo Hospital, The Hague, Netherlands, The Hague, Netherlands, 3Department of Rheumatology, HAGA hospital, The Hague, Netherlands, The Hague, Netherlands, 4Department of Rheumatology, Franciscus Hospital, Roosendaal, Netherlands, Roosendaal, Netherlands, 5Amsterdam Medical Center, Amsterdam, Netherlands, 6Zuyderland Medical Center, Heerlen, Netherlands, Heerlen, Netherlands

    Background/Purpose: Should we aim at remission if patients are in low disease activity (LDA)? We assessed if rheumatoid or undifferentiated arthritis (RA, UA) patients who…
  • Abstract Number: 2536 • 2016 ACR/ARHP Annual Meeting

    The Performance of a Single Centre Interventional Clinic in Early Rheumatoid Arthritis

    Rok Jese1, Ales Ambrozic2, Natasa Gaspersic2, Alojzija Hocevar1, Boris Lestan1, Milena Pavic Nikolic1, Martina Plešivčnik Novljan2, Sonja Praprotnik3, Ziga Rotar1, Alenka Šipek Dolničar1, Dasa Suput Skvarca1 and Matija Tomsic1, 1Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia, 2Department of Rheumatology, University Medical Centre Ljubljana, 1000 Ljubljana, Slovenia, 3Department of Rheumatology, University Medical Centre Ljubljana, Slovenia, Ljubljana, Slovenia

    Background/Purpose:  In early rheumatoid arthritis (RA), first assessment by a rheumatologist and/or initiation of disease-modifying anti-rheumatic drugs (DMARD) within 12 weeks of symptom onset are…
  • Abstract Number: 1095 • 2016 ACR/ARHP Annual Meeting

    Periarticular Bone Loss in Arthritis Is Induced By Autoantibodies Against Citrullinated Vimentin

    Cecilia Engdahl1, Holger Bang2, Katharina Dietel1, Stefanie C Lang1, Ulrike Harre1 and Georg Schett3, 1Department of Internal Medicine 3 and Institute for Clinical Immunology, Friedrich-Alexander-University Erlangen-Nuremberg (FAU), Erlangen, Germany, 2Orgentec Diagnostics, Mainz, Germany, 3Department of Internal Medicine III, Institute for Clinical Immunology,, Friedrich-Alexander-University Erlangen-Nuremberg (FAU), Erlangen, Germany

    Background/Purpose: Periarticular bone loss is a long known and early but yet insufficiently understood phenomenon in patients with rheumatoid arthritis. This study investigated whether autoimmunity…
  • « Previous Page
  • 1
  • …
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • 18
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology